Skip to main content
SP5007,798.99+0.65%DOW53,839.99+0.13%NASDAQ26,803.03+0.81%BTC$62,810.00-1.11%ETH$1,874.82-0.43%GOLD$4,429.40+0.20%OIL$82.00+0.92%
Smart Investors Daily
Sign InSign Up Free
SE

NASDAQ · SER

Serina Therapeutics, Inc.

Healthcare · Biotechnology

$2.85

Up+$0.03 (+1.06%)

Updated Aug 14, 2026, 10:53 AM

SID Score

6.0/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
33.49M
P/E ratio
-2.49
Dividend yield
0.00%
52-week range
$1.22 – $3.29
Volume
54.7K
Avg. volume
27.05K

Price performance

SER price history

1M range · 21 trading sessions · Daily adjusted prices

SER closed at $2.85 after 21 trading sessions, up 43.94% for the selected period.

Last close
$2.85
Period change
+43.94%
Period low
$1.98
Period high
$2.85
Daily close
View OHLC price history
SER OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Aug 13, 2026$2.81$2.85$2.70$2.8554.7K
Aug 12, 2026$2.80$2.82$2.675$2.82108.6K
Aug 11, 2026$2.69$2.86$2.68$2.78118.07K
Aug 10, 2026$2.37$2.73$2.31$2.67139.24K
Aug 7, 2026$2.36$2.40$2.3298$2.4026.59K
Aug 6, 2026$2.14$2.39$2.14$2.3570.99K
Aug 5, 2026$2.04$2.23$2.04$2.2335.28K
Aug 4, 2026$2.11$2.2371$2.10$2.1444.98K
Aug 3, 2026$2.00$2.11$2.00$2.0617.64K
Jul 31, 2026$2.03$2.12$2.00$2.009.7K
Jul 30, 2026$2.07$2.11$2.0001$2.0412.1K
Jul 29, 2026$2.06$2.12$2.06$2.076.32K
Jul 28, 2026$2.00$2.11$2.00$2.0727.74K
Jul 27, 2026$2.11$2.11$2.00$2.1012.55K
Jul 24, 2026$2.13$2.1499$1.98$2.0744.32K
Jul 23, 2026$2.17$2.25$2.02$2.0938.4K
Jul 22, 2026$2.13$2.281$2.10$2.1768.42K
Jul 21, 2026$2.18$2.18$2.07$2.0917.37K
Jul 20, 2026$2.13$2.19$2.04$2.1815.62K
Jul 17, 2026$2.13$2.17$2.00$2.1329.24K
Jul 16, 2026$2.02$2.06$1.97$1.9831.26K

Latest SER news

The latest Smart Investors Daily articles mentioning SER.

Stock researchCompany · Overview

SER research

Overview

Company profile and research snapshot.

Company profile

Serina Therapeutics Inc is a clinical-stage biotechnology company developing a pipeline of wholly-owned drug product candidates to treat neurological diseases and pain. Serina's POZ Platform delivery technology is engineered to provide control in drug loading and more precision in the rate of release of attached drugs, enabling the potential of certain challenging small molecules, while addressing the limitations of polyethylene glycol (PEG) and other biocompatible polymers. The Company has one reportable segment relating to the research and development of its POZ platform.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
—
Implied upside
—
Analysts
—
SER recent ratings
DateFirmRatingTarget
Jul 1, 2026BTIGBuy—
Aug 28, 2025HC Wainwright & Co.Buy—
Jul 14, 2025HC Wainwright & Co.Buy—
Mar 11, 2025Jones TradingBuy—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Jul 24, 2026

Serina Therapeutics to Participate in the BTIG Virtual Biotechnology Conference

HUNTSVILLE, Ala., July 24, 2026 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. (“Serina” or the “Company”) (NYSE American: SER), a clinical-stage biotechnology company developing its proprietary POZ Platform™ drug optimization technology, today announced that management will participate in the BTIG Virtual Biotechnology Conference, taking place July 28-29, 2026. Management will hold virtual one-on-one investor meetings on Wednesday, July 29, 2026. Please contact your BTIG representative to reques

Yahoo · Jul 23, 2026

Serina Therapeutics Announces Completion of Enrollment and Dosing in Cohort 1 of Registrational Trial of SER-252 for Advanced Parkinson’s Disease

- All eight patients enrolled and dosed in Cohort 1 ahead of previously disclosed guidance of the end of the third quarter of 2026 - - Independent Safety Monitoring Committee to review Cohort 1 safety and tolerability in accordance with the study protocol - - Company expects to provide a further update following completion of the Safety Monitoring Committee review – HUNTSVILLE, Ala., July 23, 2026 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. (“Serina” or the "Company") (NYSE American: SER), a c

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By